Skip to main content
Premium Trial:

Request an Annual Quote

ImaginAb, Neuvogen Sign Deal to Use CD8 ImmunoPET Technology in Cancer Vaccine Trials

NEW YORK – ImaginAb on Thursday said it has signed a multi-year, non-exclusive licensing agreement with Neuvogen to provide its CD8 imaging agents for use in the San Diego-based immuno-oncology firm's cancer vaccine clinical trials.

ImaginAb's 89Zr CD8 Immuno-PET imaging agent enables the tracking and quantitative imaging of CD8 T cells in order to confirm and monitor cancer immunotherapy drug activity and efficacy.

Under the terms of their agreement, Inglewood, California-headquartered ImaginAb will work with Neuvogen to implement its technology into clinical trials of the firm's therapeutic vaccine candidates, which are designed to simultaneously direct an immune response against overlapping tumor targets and multiple biologic pathways.

ImaginAb's imaging technology will allow researchers to visualize tumor infiltrating lymphocytes and monitor the dynamics of CD8 T cells in response to vaccine treatment without the need for multiple tumor biopsies.

"We believe combining CD8 imaging with Neuvogen’s whole cell cancer vaccines will enable more robust clinical data sets and accelerate the development of novel treatment protocols for solid tumors," ImaginAb CEO Ian Wilson said in a statement.

For its provision of technology, as well as technical and clinical support, ImaginAb will receive license fees and other contingent payments. No other terms of the deal were disclosed.